Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.71 |
| ▸ | PGK2 | P07205 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.68 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5381003 | 0.91 | ADORA3 (0.75) | ADORA3ADORA1SLC29A1ADORA2AADORA2B | |
| SCHEMBL4804402 | 0.91 | ADORA3 (0.74) | PGK1PGK2ADORA3ADORA1SLC29A1 | |
| SCHEMBL3955616 | 0.91 | ADORA3 (0.75) | ADORA3ADORA1SLC29A1ADORA2AADORA2B | |
| SCHEMBL13286508 | 0.91 | ADORA3 (0.74) | PGK1PGK2ADORA3ADORA1SLC29A1 | |
| SCHEMBL5383886 | 0.89 | ADORA2A (0.65) | PGK1PGK2ADORA3ADORA1SLC29A1 | |
| SCHEMBL3947852 | 0.89 | ADORA2A (0.65) | PGK1PGK2ADORA3ADORA1SLC29A1 | |
| SCHEMBL10682966 | 0.87 | PGK1 (0.69) | PGK1PGK2ADORA3ADORA1ADORA2A | |
| SCHEMBL10682972 | 0.87 | PGK1 (0.69) | PGK1PGK2ADORA3ADORA1ADORA2A | |
| SCHEMBL20626338 | 0.86 | SLC29A1 (0.82) | ADORA3ADORA1SLC29A1ADORA2ATP53 | |
| SCHEMBL20626337 | 0.86 | SLC29A1 (0.82) | ADORA3ADORA1SLC29A1ADORA2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381714-B2 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| US-20060276428-A1 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276428-A1 | A1 adenosine receptor agonists | ADORA1, ADORA2A, ADORA3 | PGK1 1806/4885PGK2 2787/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.